{
    "clinical_study": {
        "@rank": "139598", 
        "arm_group": [
            {
                "arm_group_label": "THS 2.2", 
                "arm_group_type": "Experimental", 
                "description": "Ad libitum use of THS 2.2"
            }, 
            {
                "arm_group_label": "Smoking abstinence (SA)", 
                "arm_group_type": "Sham Comparator", 
                "description": "Abstinence from smoking"
            }, 
            {
                "arm_group_label": "CC", 
                "arm_group_type": "Active Comparator", 
                "description": "Ad libitum use of CC"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall goal of the study is to evaluate if the ad libitum use of the THS 2.2 for 5\n      consecutive days by adult Japanese healthy smokers affects the levels of biomarkers of\n      exposure for selected harmful and potentially harmful constituents (HPHCs) compared to\n      smoking conventional cigarettes and smoking abstinence."
        }, 
        "brief_title": "Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is Japanese.\n\n          -  Smoking, healthy subject as judged by the Investigator.\n\n          -  Subject smokes at least 10 commercially available non-menthol CCs per day (no brand\n             restrictions) for the last 4 weeks, based on self reporting.\n\n          -  Subject has smoked for at least the last 3 consecutive years.\n\n          -  Subject does not plan to quit smoking in the next 3 months.\n\n        Exclusion Criteria:\n\n          -  As per Investigator judgment, the subject cannot participate in the study for any\n             reason (e.g., medical, psychiatric, and/or social reason).\n\n          -  The subject has received medication within 14 days or within 5 half-lives of the\n             medeication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.\n\n          -  For women: Subject is pregnant or is breast feeding.\n\n          -  For women: Subject does not agree to use an acceptable method of effective\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "23 Years"
        }, 
        "enrollment": {
            "#text": "166", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970982", 
            "org_study_id": "ZRHR-REXC-04-JP", 
            "secondary_id": "ZRHR-REXC-04-JP"
        }, 
        "intervention": [
            {
                "arm_group_label": "THS 2.2", 
                "description": "THS 2.2 ad libitum for 5 days in confinement", 
                "intervention_name": "THS 2.2 (Tobacco Heating System)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Smoking abstinence (SA)", 
                "description": "SA for 5 days in confinement", 
                "intervention_name": "SA (Smoking Abstinence)", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "CC", 
                "description": "Subject's own preferred brand of CC ad libitum for 5 days in confinement", 
                "intervention_name": "CC (Conventional Cigarettes)", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Modified risk tobacco product", 
            "Conventional cigarette", 
            "Reduced exposure", 
            "HPHCs", 
            "Confinement"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "Higashi Shinjuku Clinic, Daito Building, 1-11-3, Okubo, Shinjuku-ku"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Controlled, 3-arm Parallel Group Study to Demonstrate Reductions in Exposure to Smoke Constituents in Smoking Subjects Switching to THS 2.2 or to Smoking Abstinence, Compared to Smoking Conventional Cigarettes for 5 Days in Confinement", 
        "overall_official": [
            {
                "affiliation": "Higashi Shinjuku Clinic", 
                "last_name": "Takuya Kunito, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Philip Morris Products S.A.", 
                "last_name": "Christelle Haziza, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To demonstrate the reduction of exposure to respectively 1,3-butadiene; acrolein; benzene and carbon monoxide (HPHCs) after 5 days of switching from conventional cigarettes to THS 2.2 as compared to conventional cigarettes.", 
            "measure": "To demonstrate reduced levels of monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA); S-phenylmercapturic acid (S-PMA) expressed as concentration adjusted to creatinine in urine and carboxyhemoglobin (COHb) in blood.", 
            "safety_issue": "No", 
            "time_frame": "5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970982"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philip Morris Products S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philip Morris Products S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}